Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Clinical Hold Hits Keytruda Multiple Myeloma Studies

Executive Summary

Development of the leading immune-oncology agent has hit the buffers for multiple myeloma but failure in this relatively small market should not materially impact the product's prospects.


Related Content

Darzalex Solid Tumor And PD-(L)1 Combo Future Dashed
US FDA Tweaks IND Clinical Hold Policy As Number Of Holds Rises
Deciphering US FDA’s Keytruda Safety Announcement
FDA Eyeing Other PD-1/L1 Drugs With Clinical Hold On Keytruda Myeloma Trials
Merck's Keytruda Claims Market Leadership In First-line Lung Cancer
2Q Pharma Results Preview: Bristol, AstraZeneca, Roche, Celgene, Bayer, Merck, AbbVie & Sanofi
More Than CAR-T: Hematologic Oncology Pipeline Offers Rich Menu Of Possible Approvals
Interview: Beigene Bursts Onto World IO Scene With Celgene Onboard
Celgene Eyes IO Growth With BeiGene China Pact


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts